Mebudipine as an Overlooked Cardioprotective Drug: A Review Study

Abstract

Context: Calcium channel blockers (CCBs) play a crucial role in the treatment of cardiovascular diseases. Mebudipine, a dihydropyridine derivative CCB, was first synthesized in 1997. This study explores the potential benefits of mebudipine in managing cardiovascular disease, particularly as a derivative of nifedipine. Evidence Acquisition: The article succinctly presents the advancements in mebudipine research, which were uncovered through extensive searches in reputable scientific databases such as ScienceDirect, Google Scholar, Scopus, and PubMed, conducted by 2 blinded researchers. The search focused on studies relevant to mebudipine, using specific keywords. Results: Mebudipine exhibits cardioprotective effects, reducing the occurrence of arrhythmias and minimizing heart tissue damage. Additionally, it has been found to enhance the levels of nitric oxide metabolites. Due to its limited solubility in water, mebudipine is typically administered using a nanoemulsion. Importantly, it has been deemed a safe drug without mutagenic effects. Conclusions: Our review study underscores that mebudipine not only has a cardioprotective effect but also offers protection to other organs against various forms of injury induction. The mechanisms responsible for these protective effects may be linked to its ability to counteract oxidative stress, prevent apoptosis, and mitigate inflammation. Nevertheless, further research is needed to fully elucidate its potential.